Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus DIFICID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus DIFICID.
COR-OTICIN vs DIFICID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
1-2 drops in each affected ear twice daily for 7 days.
200 mg (tablet) orally twice daily for 10 days.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic